Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other Specified Schizophrenia Spectrum and Other Psychotic Disorder Clear all
Completed Phase 4 Interventional Results available

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

NCT00320671
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting No phase listed Observational

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

Pharmacy Interventions to Improve Chronic Disease Medication Refill

NCT00469365
View directory record Official record
Conditions
Diabetes, Hypertension, Hyperlipidemia, Heart Diseases, Depression, Psychoses
Interventions
pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
3,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2008 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

NCT03230097
View directory record Official record
Conditions
Psychotic Disorders
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
16 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Culver City, California • San Diego, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jul 23, 2026, 2:22 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Cognitive Mobile Intervention for Motivation in Psychotic Disorders

NCT07674914
View directory record Official record
Conditions
Schizophrenia / Schizoaffective Disorder
Interventions
Cognitive Training, Mobile cognitive training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Transcranial Magnetic Stimulation on Memory

NCT00105118
View directory record Official record
Conditions
Healthy, Healthy Volunteer, HV
Interventions
Magstim Super Rapid Magnetic Stimulator
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 2:22 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Jul 23, 2026, 2:22 PM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347
View directory record Official record
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT00709202
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Betahistine, Placebo Oral Tablet
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

Specialized Treatment Early in Psychosis (STEP)

NCT00309452
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features
Interventions
Cognitive Behavioral Group Therapy, Cognitive remediation, Medications, MFG, Assertive case management, Treatment as Usual in the community
Behavioral · Drug · Other
Lead sponsor
Yale University
Other
Eligibility
16 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jul 23, 2026, 2:22 PM EDT
Active, not recruiting Not applicable Interventional

Young Adults With Violent Behavior During Early Psychosis (Aim 2)

NCT05756855
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder, Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
adapted behavioral intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
16 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

NCT01570972
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis

NCT01196286
View directory record Official record
Conditions
Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated No phase listed Observational

Social Cognition in Longstanding Psychosis

NCT01624831
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychosis Not Otherwise Specified (NOS)
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

MicroRNAs as Biomarkers in First Episode Schizophrenia

NCT07703670
View directory record Official record
Conditions
Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Plasma NDE miRNA Sequencing, Whole Genome Sequencing
Diagnostic Test · Genetic
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 4 Interventional Results available

Optimizing Response in Psychosis Study

NCT00314327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Brooklyn, New York • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

NCT01878513
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
Interventions
risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jul 23, 2026, 2:22 PM EDT